Fenella Barlow-Pay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fenella Barlow-Pay has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Ben Carter
Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
2 shared publications - Eilidh Bruce
Department of Breast Surgery, Aberdeen Royal Infirmary, NHS Grampian, AB25 2ZN Aberdeen, Scotland, UK; University of Aberdeen, AB25 2ZN Aberdeen, Scotland, UK
2 shared publications - Philip Braude
CLARITY (Collaborative Ageing Research), North Bristol Trust, Bristol, UK
2 shared publications - Roxanna Short
King's College London
2 shared publications - Susan Joan Moug
Department of Surgery Royal Alexandra Hospital Paisley UK
2 shared publications - Aine McGovern
Glasgow Royal Infirmary, Glasgow G4 0SF, Scotland, UK
1 shared publication
Latest Publications
- Open Access
- 1 December 2020
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 31, 100660
The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19
- 1 December 2020
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 31, 100660
Open AccessThe influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19
- Open Access
- 10 August 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (8) , 2586
Prior Routine Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Important Outcomes in Hospitalised Patients with COVID-19
Coronavirus disease 2019 (COVID-19) infection causes acute lung injury, resulting from aggressive inflammation initiated by viral replication. There has been much speculation about the potential role of non-steroidal inflammatory drugs (NSAIDs), which increase the expression of angiotensin-converting enzyme 2 (ACE2), a binding target for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter the host cell, which could lead to poorer outcomes in COVID-19 disease. The aim of this study was to examine the association between routine use of NSAIDs and outcomes in hospitalised patients with COVID-19. This was a multicentre, observational study, with data collected from adult patients with COVID-19 admitted to eight UK hospitals. Of 1222 patients eligible to be included, 54 (4.4%) were routinely prescribed NSAIDs prior to admission. Univariate results suggested a modest protective effect from the use of NSAIDs, but in the multivariable analysis, there was no association between prior NSAID use and time to mortality (adjusted HR (aHR) = 0.89, 95% CI 0.52–1.53, p = 0.67) or length of stay (aHR 0.89, 95% CI 0.59–1.35, p = 0.58). This study found no evidence that routine NSAID use was associated with higher COVID-19 mortality in hospitalised patients; therefore, patients should be advised to continue taking these medications until further evidence emerges. Our findings suggest that NSAID use might confer a modest benefit with regard to survival. However, as this finding was underpowered, further research is required.
- 10 August 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (8) , 2586
Open AccessPrior Routine Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Important Outcomes in Hospitalised Patients with COVID-19
Coronavirus disease 2019 (COVID-19) infection causes acute lung injury, resulting from aggressive inflammation initiated by viral replication. There has been much speculation about the potential role of non-steroidal inflammatory drugs (NSAIDs), which increase the expression of angiotensin-converting enzyme 2 (ACE2), a binding target for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter the host cell, which could lead to poorer outcomes in COVID-19 disease. The aim of this study was to examine the association between routine use of NSAIDs and outcomes in hospitalised patients with COVID-19. This was a multicentre, observational study, with data collected from adult patients with COVID-19 admitted to eight UK hospitals. Of 1222 patients eligible to be included, 54 (4.4%) were routinely prescribed NSAIDs prior to admission. Univariate results suggested a modest protective effect from the use of NSAIDs, but in the multivariable analysis, there was no association between prior NSAID use and time to mortality (adjusted HR (aHR) = 0.89, 95% CI 0.52–1.53, p = 0.67) or length of stay (aHR 0.89, 95% CI 0.59–1.35, p = 0.58). This study found no evidence that routine NSAID use was associated with higher COVID-19 mortality in hospitalised patients; therefore, patients should be advised to continue taking these medications until further evidence emerges. Our findings suggest that NSAID use might confer a modest benefit with regard to survival. However, as this finding was underpowered, further research is required.
- Open Access
- 7 May 2019
- Published by Wiley in Anaesthesia
- Vol. 74 (6) , 811
Electroshock from a nerve stimulator charging cable
- 7 May 2019
- Published by Wiley in Anaesthesia
- Vol. 74 (6) , 811
Open AccessElectroshock from a nerve stimulator charging cable